SCHEMBL4292341

SCHEMBL4292341

CCCCC(=O)N(c1ccc(C2CCC3CCCCN32)cc1)C1CCCNC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.40
HRH3 Q9Y5N1 1/20 0.36
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
RPLP1 P05386 7/20 0.34
RPLP0 P05388 7/20 0.34
RPS17 P08708 7/20 0.34
RPSA P08865 7/20 0.34
RPS2 P15880 7/20 0.34
RPL35A P18077 7/20 0.34
RPL7 P18124 7/20 0.34
RPL17 P18621 7/20 0.34
RPS4Y1 P22090 7/20 0.34
RPS3 P23396 7/20 0.34
RPS12 P25398 7/20 0.34
RPL13 P26373 7/20 0.34
RPL10 P27635 7/20 0.34
RPL12 P30050 7/20 0.34
RPL9; RPL9P7; RPL9P8; RPL9P9 P32969 7/20 0.34
RPL22 P35268 7/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4292339 1.00 OPRM1 (0.40) OPRM1HRH3SLC6A2SLC6A4RPLP1
SCHEMBL4292343 1.00 OPRM1 (0.40) OPRM1HRH3SLC6A2SLC6A4RPLP1
SCHEMBL4301772 0.91 HRH3 (0.39) OPRM1HRH3RPLP1RPLP0RPS17
SCHEMBL4301777 0.91 HRH3 (0.39) OPRM1HRH3RPLP1RPLP0RPS17
SCHEMBL4301775 0.91 HRH3 (0.39) OPRM1HRH3RPLP1RPLP0RPS17
SCHEMBL4296089 0.85 OPRM1 (0.42) OPRM1HRH3CA12CA1CA2
SCHEMBL4295444 0.85 TACR1 (0.40) OPRM1HRH3SLC6A2SLC6A4KCNH2
SCHEMBL4295450 0.85 TACR1 (0.40) OPRM1HRH3SLC6A2SLC6A4KCNH2
SCHEMBL4295438 0.85 TACR1 (0.40) OPRM1HRH3SLC6A2SLC6A4KCNH2
SCHEMBL7105668 0.81 HRH3 (0.40) HRH3SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090263322-A1 OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES APODACA RICHARD 2009-10-22 US claimed
US-20050288323-A1 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine APODACA RICHARD 2005-12-29 US claimed
US-20040167336-A1 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine APODACA RICHARD (US) 2004-08-26 US claimed
US-20030013733-A1 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-01-16 US claimed
US-20090263322-A1 OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES APODACA RICHARD 2009-10-22 US disclosed
US-20050288323-A1 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine APODACA RICHARD 2005-12-29 US disclosed
US-20040167336-A1 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine APODACA RICHARD (US) 2004-08-26 US disclosed
US-20030013733-A1 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288323-A1 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine HRH4, HNMT, HRH1 OPRM1 49/4885HRH3 7/4885SLC6A2 644/4885
US-20030013733-A1 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine HRH4, HNMT, HRH1 OPRM1 49/4885HRH3 7/4885SLC6A2 644/4885
US-20040167336-A1 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine HRH4, HNMT, HRH1 OPRM1 49/4885HRH3 7/4885SLC6A2 644/4885
US-20090263322-A1 OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES HRH4, HNMT, HRH1 OPRM1 51/4885HRH3 7/4885SLC6A2 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.